Arecor Therapeutics PLC (GB:AREC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Arecor Therapeutics PLC reports positive interim results, including a successful Phase I trial for its insulin candidate AT278 and the expansion of its diabetes and obesity pipeline. The company’s financial position is strengthened by a £6.4 million fundraise, which will support further R&D and sales of Ogluo®, their specialty diabetes product. Arecor’s growing technology partnerships and licensing agreements signal potential future revenue growth.
For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.